SCHEMBL6700205

SCHEMBL6700205

Cc1ccc(OBOc2ccc(C)s2)s1

nearest known ligand 0.33

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.33
MAPT P10636 2/20 0.33
ALDH1A1 P00352 1/20 0.33
GFER P55789 1/20 0.33
HSD17B10 Q99714 1/20 0.33
DAO P14920 1/20 0.33
CASP3 P42574 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
PRMT6 Q96LA8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434813 0.74
SCHEMBL15241843 0.72
SCHEMBL14960905 0.72
SCHEMBL5209319 0.70 DAO (0.33) NPC1MAPTDAOCASP3RAB9A
SCHEMBL8780853 0.67 MAPT (0.48) NPC1MAPTALDH1A1GFERHSD17B10
SCHEMBL64283 0.67
SCHEMBL12778099 0.67 DAO (0.31) NPC1MAPTDAOCASP3RAB9A
SCHEMBL4570687 0.67
SCHEMBL12666964 0.67
SCHEMBL13665358 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825222-B2 2-(4-(2-(2-BIPHENYL-YL-5-METHYL-THIAZOL-4-YL)-ALKOXY)-PHENOXY) -2-METHYL-PROPIONIC ACID DERIVATIVES; ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2004-11-30 US disclosed
US-20040019090-A1 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents ELI LILLY & COMPANY 2004-01-29 US disclosed
EP-1206457-B1 BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS LILLY CO ELI (US) 2003-10-15 EP disclosed
US-6610696-B2 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides) ELI LILLY AND COMPANY 2003-08-26 US disclosed
US-20030045558-A1 Modulators of peroxisome proliferator activated receptors ELI LILLY & COMPANY LILY CORPORATE CENTER (US) 2003-03-06 US disclosed
WO-2001016120-A9 BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS LILLY CO ELI (US) 2002-07-11 WO disclosed
US-6417212-B1 PHENYLOXAZOLE SUBSTITUTED ON BENZENEOXYPROPIONIC ACID OR ESTERS ELI LILLY & COMPANY 2002-07-09 US disclosed
EP-1206457-A1 BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS ELI LILLY AND COMPANY (US) 2002-05-22 EP disclosed
WO-2001016120-A1 BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS ELI LILLY AND COMPANY (US) 2001-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019090-A1 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents SLC5A2, SLC5A1, GLP1R NPC1 391/4885MAPT 3558/4885ALDH1A1 617/4885
US-20030045558-A1 Modulators of peroxisome proliferator activated receptors PPARG, PPARA, PPARD NPC1 291/4885MAPT 4711/4885ALDH1A1 940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.